CHMMF - Chimeric Therapeutics Limited
NYSE * Healthcare * Biotechnology
$0.00
+$0.00 (+0.00%)
About Chimeric Therapeutics Limited
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurrent or progressive glioblastoma and membrane-bound matrix metalloproteinase-2 (MMP2) expressing solid tumors. It also develops CHM CORE-NK for the treatment of acute myeloid leukaemia/colorectal cancer, acute myeloid cancer, blood cancer, solid tumors, MMP2 expressing solid tumors, and CDH17 expressing solid tumors. The company was incorporated in 2020 and is based in Carlton, Australia.
CHMMF Key Statistics
Market Cap
$4.42M
P/B Ratio
0.54
EPS
$-0.01
Revenue Growth
-0.5%
Profit Margin
-1.9%
How CHMMF Compares to Peers
P/E Rank
N/A
of 5
Margin Rank
#6
of 6
Growth Rank
#6
of 6
Size Rank
#6
of 6
Chimeric Therapeutics Limited Company Information
- Headquarters
- 62 Lygon Street, Carlton, VIC, Australia, 3053, undefined
- Website
- www.chimerictherapeutics.com
- Sector
- Healthcare
- Industry
- Biotechnology